Gilead-partnered Glympse snares $46.7M for their NASH-snooping biosensors
Since its emergence at JP Morgan six years ago, the NASH field has been held back not only by the question of how to treat the disease, but also by the question of how you diagnose it. It’s simply not that difficult to tell if a liver is fatty or scarred or in full-on cirrhosis.
The method used in most trials is needle biopsy, where you take a hollow needle, stick it through someone’s skin and into their liver and suck out some cells. You stain those cells and examine them under the microscope. It’s safe but very painful, and that pain limits how often you can test a patient in a trial, and, down the line, how many of the millions of Americans suspected to have NASH would actually be tested for the disease and potentially prescribed an approved drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
